Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002715 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00002715: Completed Phase 2 study, sponsored by Stanford University.
NCT00002715 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002715, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced Hodgkin's lymphoma.
Interventions
- DRUG Etoposide
- DRUG Doxorubicin hydrochloride
- DRUG Stanford V regimen
- BIOLOGICAL Bleomycin sulfate
- DRUG Mechlorethamine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 1989-04 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002715
The ClinicalTrials.gov registry entry for NCT00002715 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Etoposide is the first listed.
NCT00002715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002715 about?
NCT00002715 is a clinical study titled "Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced Hodgk...
What is the current status of trial NCT00002715?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 1989-04. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00002715?
The interventions under investigation include: Etoposide (DRUG), Doxorubicin hydrochloride (DRUG), Stanford V regimen (DRUG), Bleomycin sulfate (BIOLOGICAL), Mechlorethamine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002715?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.